For this purpose, the treating doctors needed a modern real-time PCR device. This was financed by the Regine Sixt Children’s Aid Foundation Drying Tears in order to significantly improve the treatment of the young patients in the future. The modern real-time PCR device makes it possible, among other things, to validate the reading of tumor-specific genes in the tumor tissue of each patient. With this so-called gene expression pattern of the tumor, individual cell-based cancer therapies are possible, which in individual cases offer a chance of cure even in the case of relapse of the disease – even in the case of already metastasized disease. In the future, about 10 to 12 small patients per year will benefit from this.
Prof. Dr. med. Stefan Burdach, head of the Translational Pediatric Oncology Research Group at the Technical University of Munich: “With the new state-of-the-art real-time PCR device, we are now able to identify the gene expression pattern of a tumor and derive an individualized drug- or cell-based therapy for the diseased child – an enormous help and prerequisite for successful treatment. It is especially important that the toxic side effects of conventional treatments can be avoided for these children who have suffered through a long history of the disease. We say from the bottom of our hearts: ‘Thank you’ to the RegineSixt Children’s Aid Foundation.”
Donation of a PCR device to the pediatric clinic Schwabing
“In Germany today, 4 out of 5 children with cancer recover. However, with certain cancers and advanced stages of the disease, the chances of recovery are many times lower. That is why I am particularly pleased to be able to help the Munich Schwabing Children’s Hospital improve the treatment of children with cancer with the new device. After all, it is precisely the youngest among us who should have access to the best possible healthcare,” says Regine Sixt, Chairwoman of the Board of the Regine Sixt Children’s Aid Foundation Drying Tears.